Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

Sotirios TsimikasEwa Karwatowska-ProkopczukIoanna Gouni-BertholdJean-Claude TardifSeth J BaumElizabeth Steinhagen-ThiessenMichael D ShapiroErik S StroesPatrick M MoriartyBørge G NordestgaardShuting XiaJonathan GuerrieroNicholas J VineyLouis O'DeaJoseph L Witztumnull null

Published in: The New England journal of medicine (2020)

APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

Keyphrases

cardiovascular disease
low density lipoprotein
type diabetes
cardiovascular events